OVERCOME CANCER RESISTANCE
NETRIS Pharma develops first-in-class therapeutics to overcome resistance in oncology by targeting Netrin-1
Best-in-Class Environment to foster Therapeutic Innovation
NETRIS Pharma is the first spin-off of Centre Léon Bérard and the Cancer Research Center of Lyon – CRCL – (Lyon, France) and benefits from the exceptional environment of this world’s renowned comprehensive center dedicated to cancer care, education and research.
Our news
04/25/2025
NETRIS Pharma Announces Positive Interim Phase II Results for NP137 in combination with anti-PD(L)1
12/03/2024
NETRIS Pharma Welcomes Eric Falcand as Independent Director to Its Board of Directors
11/21/2024
NETRIS Pharma Announces FDA Orphan Drug Designation (ODD) for NP137 in Pancreatic Cancer Treatment
Our publications
10/18/2024
Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling
08/30/2023
Blockade of netrin-1 is a promising strategy against endometrial cancer - Clinical briefing
08/30/2023
Pharmacological targeting netrin-1 inhibits EMT in cancer
Strategic Focus on Intellectual Property Rights
As the world pioneer and leader biopharmaceutical company targeting netrin-1 and ligands of Dependence Receptors, NETRIS Pharma is building a unique portfolio of worldwide exclusive rights and patents on all key elements of its approach.
Our partners
NETRIS Pharma has grown from inception with the full support of Research, Clinical and Corporate Partners.
Clinical
Corporate
Research
